Skip to content

Study · Non-randomized trial · n = 5 · 1990

4 results

Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion.

Ambrosi B, Bochicchio D, Fadin C, Colombo P, Faglia G

Journal of endocrinological investigation1 Mar 1990Cited by 51 (Europe PMC)

PMID1973178 (opens in a new tab)DOI10.1007/bf03349555 (opens in a new tab)PepBankPUB-01973178
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In Cushing's disease, ACTH responses to CRH were similar before octreotide (9.9 +/- 1.7 to 19.4 +/- 6.1 pmol/L) and after it (8.8 +/- 2.4 to 19.1 +/- 8.2 pmol/L).

    In plain wordsIn Cushing's disease, ACTH responses to CRH were similar before and after octreotide.

    Peptide
    Octreotide
    Outcome
    No significant changeACTH response to CRH
    Study

    n = 5

    Comparator
    CRH response before octreotide
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Plasma ACTH, start of CRH response
    9.9 pmol/L
    before octreotide, SD 1.7
    Plasma ACTH, end of CRH response
    19.4 pmol/L
    before octreotide, SD 6.1
    Plasma ACTH, start of CRH response
    8.8 pmol/L
    after octreotide, SD 2.4
    Plasma ACTH, end of CRH response
    19.1 pmol/L
    after octreotide, SD 8.2

    Source sentences

    Summary
    In 5 patients with Cushing's disease the plasma ACTH and cortisol responses to CRH were similar both before (ACTH from 9.9 +/- 1.7 pmol/L to 19.4 +/- 6.1 pmol/L; cortisol from 496 +/- 43.9 nmol/L to 923 +/- 355 nmol/L) and after octreotide injection (ACTH from 8.8 +/- 2.4 pmol/L to 19.1 +/- 8.2 pmol…
    3 context sentences
    Summary · context
    In 5 other patients with Cushing's disease ACTH and cortisol responses to CRH (1 microgram/kg iv) were evaluated in basal conditions and after octreotide acute administration.
    Summary · context
    In this study we investigated the effects of somatostatin or octreotide on ACTH levels of patients with corticotropin hypersecretion: 7 patients with Addison's disease, 2 patients previously adrenalectomized for Cushing's disease, 4 patients with Cushing's disease and 3 patients with ectopic ACTH syndrome.
    Summary · context
    Plasma ACTH and cortisol levels were determined after somatostatin (500 micrograms over 60 min) infusion or octreotide (100 micrograms sc) injection.
  2. 02HumanNon-randomized trialEfficacy outcome

    In Cushing's disease, cortisol responses to CRH were similar before octreotide (496 +/- 43.9 to 923 +/- 355 nmol/L) and after it (510 +/- 54.6 to 735 +/- 220 nmol/L).

    In plain wordsIn Cushing's disease, cortisol responses to CRH were similar before and after octreotide.

    Peptide
    Octreotide
    Outcome
    No significant changeCortisol response to CRH
    Study

    n = 5

    Comparator
    CRH response before octreotide
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Plasma cortisol, start of CRH response
    496 nmol/L
    before octreotide, SD 43.9
    Plasma cortisol, end of CRH response
    923 nmol/L
    before octreotide, SD 355
    Plasma cortisol, start of CRH response
    510 nmol/L
    after octreotide, SD 54.6
    Plasma cortisol, end of CRH response
    735 nmol/L
    after octreotide, SD 220

    Source sentences

    Summary
    In 5 patients with Cushing's disease the plasma ACTH and cortisol responses to CRH were similar both before (ACTH from 9.9 +/- 1.7 pmol/L to 19.4 +/- 6.1 pmol/L; cortisol from 496 +/- 43.9 nmol/L to 923 +/- 355 nmol/L) and after octreotide injection (ACTH from 8.8 +/- 2.4 pmol/L to 19.1 +/- 8.2 pmol…
    3 context sentences
    Summary · context
    In 5 other patients with Cushing's disease ACTH and cortisol responses to CRH (1 microgram/kg iv) were evaluated in basal conditions and after octreotide acute administration.
    Summary · context
    In this study we investigated the effects of somatostatin or octreotide on ACTH levels of patients with corticotropin hypersecretion: 7 patients with Addison's disease, 2 patients previously adrenalectomized for Cushing's disease, 4 patients with Cushing's disease and 3 patients with ectopic ACTH syndrome.
    Summary · context
    Plasma ACTH and cortisol levels were determined after somatostatin (500 micrograms over 60 min) infusion or octreotide (100 micrograms sc) injection.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with Cushing's syndrome, octreotide did not affect plasma ACTH levels.

    In plain wordsIn patients with Cushing's syndrome, octreotide did not change plasma ACTH levels.

    Peptide
    Octreotide
    Outcome
    No significant changeACTH in Cushing's syndrome
    Study

    n = 4

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    100 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    in other 4 patients with Cushing's syndrome octreotide did not affect plasma ACTH levels.
    2 context sentences
    Summary · context
    In this study we investigated the effects of somatostatin or octreotide on ACTH levels of patients with corticotropin hypersecretion: 7 patients with Addison's disease, 2 patients previously adrenalectomized for Cushing's disease, 4 patients with Cushing's disease and 3 patients with ectopic ACTH syndrome.
    Summary · context
    Plasma ACTH and cortisol levels were determined after somatostatin (500 micrograms over 60 min) infusion or octreotide (100 micrograms sc) injection.
  4. 04HumanNon-randomized trialEfficacy outcome

    In Addison's disease, octreotide did not inhibit plasma ACTH: delta was -38 +/- 12% versus -39 +/- 12% after saline.

    In plain wordsIn Addison's disease, octreotide did not inhibit ACTH compared with saline.

    Peptide
    Octreotide
    Outcome
    No significant changeACTH in Addison's disease
    Study

    n: not reported in source

    Comparator
    Saline
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    100 micrograms · subcutaneousAs given in this study (human).

    Measurements

    Plasma ACTH change
    −38%
    octreotide, Addison's disease, SD 12
    Plasma ACTH change
    −39%
    saline, Addison's disease, SD 12

    Source sentences

    Summary
    In no patients with Addison's disease any inhibitory influence of somatostatin (delta % = -21, -25) or octreotide (delta % = -38 +/- 12 vs -39 +/- 12 after saline) on plasma ACTH was found.
    2 context sentences
    Summary · context
    In this study we investigated the effects of somatostatin or octreotide on ACTH levels of patients with corticotropin hypersecretion: 7 patients with Addison's disease, 2 patients previously adrenalectomized for Cushing's disease, 4 patients with Cushing's disease and 3 patients with ectopic ACTH syndrome.
    Summary · context
    Plasma ACTH and cortisol levels were determined after somatostatin (500 micrograms over 60 min) infusion or octreotide (100 micrograms sc) injection.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.